Inspiration Healthcare Group PLC (LSE:IHC) has spent eighteen months rebuilding itself from a loss-making, over-stocked MedTech distributor into a leaner company focused on one thing: keeping premature babies breathing. Results for the year to 31 January 2026, published on 16 June 2026, showed Revenue up 24% to £47.5m, a return to adjusted operating profit and net Debt cut by 39%. Two weeks earlier, the Croydon-based group had announced it would hand back its UK infusion-pump distribution Business to focus purely on neonatal care.

The question now is whether that momentum has carried into the current year. At its AGM on 23 July, the board said it was "encouraged" by early trading and promised a half-year update in early September. For a small-cap that rarely makes headlines, that update could prompt the market to take another look.

Final results and a strategic pivot: FY26 revenue up 24%, infusion business handed back

The most important development pairs the FY26 final results with the 2 June 2026 announcement that Inspiration Healthcare will transfer its UK distribution of ambulatory infusion pumps and consumables back to the manufacturer, Micrel Medical Devices SA, when the distribution agreement expires on 31 January 2027.

The infusion line generated £9.7m of revenue in the year to 31 January 2026, roughly a fifth of group sales, at a contribution Margin of about 25%. Micrel will buy unsold inventory and make a compensation payment for an orderly transition and goodwill. Management expects the savings and that payment to cut net debt by around 20% in FY27 from the £5.1m year-end baseline. FY27 revenue and Gross Profit are unaffected; affected staff moved to Micrel under TUPE on 1 July 2026.

Chief executive Raffi Stepanian said the separation "allows the Group to focus on its core business of neonatology and neonatal ventilation in particular." In the results statement he called FY26 "a transformational year," with the group "positioned to scale through our three core platforms." The cost, which the board has acknowledged, is a smaller revenue base from FY28.

What Inspiration Healthcare does

Inspiration Healthcare is a medical technology group specialising in neonatal intensive care devices, with Manufacturing in Croydon and Melbourne, Florida. It reports across three platforms.

SLE designs and builds neonatal ventilators. The flagship SLE6000 serves high-acuity intensive care units, while the SLE1500 has been repositioned for step-down units, transport and delivery rooms. SLE generated £31.5m of FY26 revenue, up 56%.

Inspiration Healthcare Ltd is the UK and Ireland distribution arm spanning neonatal care and infusion therapies. It contributed £13.9m in FY26, down 11%, and will shrink once the infusion products leave.

Airon, in Florida, makes pneumatic ventilators that run without electronics or batteries, suited to emergency and transport use. It contributed £2.1m, down 13%, but in January 2026 signed a multi-year agreement with a leading US healthcare provider, including an initial order for 150 ventilators shipped in the first quarter of FY27. In FY26, 63% of group revenue came from outside the UK, with Asia-Pacific contributing £18.7m against £17.1m from the UK.

FY26 in numbers: back to profit, debt down, Dividend still suspended

For the year ended 31 January 2026, revenue rose 24% to £47.5m from £38.3m. Gross profit increased 27% to £20.8m, lifting gross margin to 43.7% from 42.8%. Adjusted EBITDA jumped to £2.8m from £0.2m, and the group swung to an adjusted operating profit of £0.8m from a £1.9m loss.

Statutory figures improved sharply, though the group stayed in the red. The operating loss narrowed to £0.1m from £14.7m, the prior year having absorbed a £10.3m Impairment among £12.8m of non-recurring charges. Loss before tax was £1.0m against £15.7m, and basic loss per share was 1.16p compared with 18.82p.

The headline growth needs context. SLE benefited from £9.5m of one-off export revenue, chiefly the group's largest ever order, from a global humanitarian aid organisation in Central Asia. Excluding that, underlying SLE growth was 10% and group revenue would have been broadly flat at around £38m.

Cash generation was the standout. A 33% cut in inventory to £8.8m helped produce operating cash inflow of £7.5m against a £1.5m outflow the year before. Net debt excluding leases fell to £5.1m from £8.3m, with £4.0m drawn on a £10m revolving Credit Facility and £2.3m on a £5m invoice finance line. No final dividend was recommended while debt reduction remains the priority.

What could drive the stock next?

The most immediate catalyst is the trading update for the six months to 31 July 2026, promised for early September. Investors will look for confirmation that trading remains "in line with Board expectations for FY27" and that underlying SLE growth is continuing without one-off export orders.

Product milestones follow. A consumables range is scheduled for launch in FY27, offering Recurring Revenue alongside the installed ventilator base, and the Airon US agreement should add consumables and service income. Management has also identified a new ventilator technology platform as a potential acquisition, although no deal has been announced.

Balance-sheet events matter too. The Micrel payment should land around the end of FY27, and the RCF expires in February 2027 with a one-year extension option. A refinancing on better terms, or a resumed dividend, would signal that the turnaround has matured.

Risks investors should watch

The most obvious risk is revenue attrition. Losing £9.7m of infusion sales from FY28 removes about a fifth of the top line, and SLE and Airon must grow enough to Fill the gap. Lumpy export orders cut both ways too: FY26 was flattered by £9.5m of one-off business, and without a repeat, reported growth could look weak even if the core is healthy.

Regulatory timing is another concern. The FDA filing for SLE ventilators has slipped to late 2027, attributed to changes for the US market and the FDA's approach, delaying access to the world's largest medtech market.

Financial headroom is modest. The group remains loss-making before tax, carries £5.1m of net debt, faces quarterly covenant tests (interest cover above 3.0x, Leverage below 2.0x) and must renew its RCF within six months. The July Withdrawal of AGM resolutions on pre-emption disapplication and buybacks, after feedback from a significant shareholder, shows investors are watching Capital allocation closely.

Outlook

Inspiration Healthcare (LSE:IHC) enters the second half of FY27 with a simpler story: a neonatal ventilation specialist with growing international reach, improving cash generation and a repairing balance sheet. The board's stated confidence extends to FY28 despite the infusion exit, and its going-concern assessment covers 18 months including transfer scenarios.

What remains unproven is whether SLE and Airon can grow fast enough to replace the lost distribution revenue and lift statutory profit into the black. The September trading update, the consumables launch, the RCF renewal and the FDA filing are the markers to monitor. On the evidence of FY26 the turnaround is real; whether it becomes one of the year's overlooked stories depends on execution.